Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs McKesson Corporation (MCK) Price & Performance

Global X Artificial Intelligence & Technology ETFTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Global X Artificial Intelligence & Technology ETF vs McKesson Corporation — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.82, while McKesson Corporation trades at $877.9 (market cap $105.14B). The key difference: McKesson Corporation pays a 0.42% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.

AIQMCK
Sector
Sector/ThematicHealth
52-Week High
$70.14$995.69
52-Week Low
$43.88$659.01
Market Cap
$105.14B
Enterprise Value
$111.67B
Dividend Yield
0.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Artificial Intelligence & Technology ETF

AIQ (Global X Artificial Intelligence & Technology ETF) trades at $63.77, up 0.41% with strong bullish momentum. Technical indicators show the stock above key moving averages with RSI suggesting mild overbought conditions. Recent news highlights AIQ's outperformance versus the Nasdaq, gaining 25% while attracting attention as a diversified AI play beyond semiconductor stocks. The ETF's systematic rebalancing approach positions it well for the evolving AI investment landscape.

AIQ offers exposure to the growing artificial intelligence sector with reduced single-stock risk. Key catalysts include upcoming AI company IPOs and federal quantum computing funding. Risks include thematic ETF volatility and premium fees compared to broader indices. The stock's proximity to resistance levels near $64 suggests potential near-term consolidation before further upside.

McKesson Corporation

McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.

MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Artificial Intelligence & Technology ETF

AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.

Read more on AIQ

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK